Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Dec 23, 2024
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Stock Option (Right to Buy)
2024-12-23+1,135,000→ 1,135,000 totalExercise: $1.67Exp: 2034-12-23→ Common Stock (1,135,000 underlying)
Footnotes (1)
- [F1]The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date.